title: Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol? The HDL-Atherosclerosis Treatment Study Design.
abstract: Evidence supports the idea that substantial benefits may derive from treatments that increase high density lipoprotein (HDL) cholesterol (HDL-C), apolipoprotein (apo) A-I, HDL2 (or 2b) or the size of HDL particles with, or without, apo A-II. HDL3 appears to be neutral in terms of coronary artery disease risk, and apo A-II appears to be adverse. Because HDL particles serve as antioxidants in vitro, the hypothesis that low HDL-C reflects an antioxidant deficiency state appears tenable. Based on these observations, a three-year angiographic study was proposed and received funding. Enrollment began in January 1995 and was completed in January 1997.
authors.affiliation: Department of Medicine, University of Washington School of Medicine, Seattle, USA. bgbrown@u.washington.edu
authors.forename: B G
authors.initials: BG
authors.lastname: Brown
authors.forename: X Q
authors.initials: XQ
authors.lastname: Zhao
authors.forename: A
authors.initials: A
authors.lastname: Chait
authors.forename: J
authors.initials: J
authors.lastname: Frohlich
authors.forename: M
authors.initials: M
authors.lastname: Cheung
authors.forename: N
authors.initials: N
authors.lastname: Heise
authors.forename: A
authors.initials: A
authors.lastname: Dowdy
authors.forename: D
authors.initials: D
authors.lastname: DeAngelis
authors.forename: L D
authors.initials: LD
authors.lastname: Fisher
authors.forename: J
authors.initials: J
authors.lastname: Albers
mesh_terms: D000328:Adult; D000368:Aged; D000975:Antioxidants / Q000009:adverse effects / Q000627:therapeutic use*; D008076:Cholesterol, HDL / Q000097:blood*; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000097:blood / Q000188:drug therapy*; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008148:Lovastatin / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009204:Myocardial Revascularization; D009525:Niacin / Q000009:adverse effects / Q000627:therapeutic use; D019821:Simvastatin / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D014815:Vitamins / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000975:Antioxidants; D008076:Cholesterol, HDL; D000960:Hypolipidemic Agents; D014815:Vitamins; D009525:Niacin; D008148:Lovastatin; D019821:Simvastatin